# Biospecimen Core

> **NIH NIH P50** · NORTHWESTERN UNIVERSITY · 2021 · $200,942

## Abstract

CORE C: ABSTRACT
Prospective procurement of biologic samples from prostate cancer patients along with accurate and detailed
clinical and pathological data is key to the success of translational research, and its ultimate goal of improvement
in the early detection, diagnosis and treatment of prostate cancer. SPORE sample procurement encompasses
the rapid collection and storage of frozen tissue, blood (serum, plasma, peripheral blood mononuclear cells, and
blood spots) and urine. Corresponding formalin-fixed paraffin-embedded (FFPE) tissue is available on each
case, and biopsies are available in many cases as well (including some metastatic cases). In the SPORE
renewal, the Biospecimen Pathology Core will continue with the following Specific Aims:
Specific Aim 1: Prospective procurement and storage of human prostate tissue and other samples and
associated data from consented patients at Northwestern University (NU) and University of Chicago (UC)
hospital affiliates, in accordance with IRB regulations:
 a. Freshly frozen prostate tissue, including malignant, premalignant and benign tissues
 b. Serum, plasma and blood samples
 c. Urine
 d. Prostatic fluid (as needed)
 e. Prostate needle biopsies
 f. Archived formalin-fixed paraffin-embedded (FFPE) tissues
 g. Genomic DNA isolation from whole blood
Specific Aim 2: To provide high quality histopathology review and quality control of specimens and pathology
data with entry into the centralized SPORE database
Specific Aim 3: To distribute well annotated samples to investigators conducting translational research after
approval by the IRB and SPORE Tissue Review and Disbursement Committee.
Specific Aim 4: To support SPORE projects and other translational research activities through histology,
immunohistochemistry, laser capture microscopy, DNA and RNA preparation, and other specialized services on
human and mouse tissues, including advanced immunophenotyping in conjunction with the Immune Assessment
Cores at NU and UC.
Specific Aim 5: To develop an innovative cfDNA hydroxymethylation assay that will support clinical trial
activities associated with SPORE Projects

## Key facts

- **NIH application ID:** 10089062
- **Project number:** 2P50CA180995-06A1
- **Recipient organization:** NORTHWESTERN UNIVERSITY
- **Principal Investigator:** XIMING J YANG
- **Activity code:** P50 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $200,942
- **Award type:** 2
- **Project period:** 2015-08-18 → 2026-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10089062

## Citation

> US National Institutes of Health, RePORTER application 10089062, Biospecimen Core (2P50CA180995-06A1). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10089062. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*